NCT06598969 - TMLI Plus Chemotherapy in High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 30, 2024

Primary Completion Date

December 30, 2026

Study Completion Date

December 30, 2028

Conditions

Myelodysplastic SyndromesMyeloid Leukemia, Acute

Interventions

DRUG

Total bone marrow and lymphoid irradiation/cyclophosphamide/etoposide

Evaluate the antileukemic activity of an total bone marrow and lymphoid irradiation/cyclophosphamide/etoposide conditioning regimen for allogeneic hematopoietic stem cell transplantation

Trial Locations (1)

41013

Hospital Universitario Virgen del Rocío, Seville

All Listed Sponsors

lead

Fundación Pública Andaluza para la gestión de la Investigación en Sevilla

OTHER